# Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer

> **NCT02558959** · PHASE2 · COMPLETED · sponsor: **Zhejiang University** · enrollment: 64 (actual)

## Conditions studied

- Biliary Tract Neoplasms

## Interventions

- **DRUG:** Irinotecan
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT02558959
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-01
- **Primary completion:** 2017-09-30
- **Final completion:** 2017-12-31
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2018-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02558959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02558959, "Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT02558959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*